| Abstrakt: |
A recent study conducted by the University of Warmia and Mazury in Olsztyn, Poland, aimed to analyze the characteristics, prognostic factors, and treatment outcomes of patients with newly diagnosed non-secretory multiple myeloma (NSMM). NSMM is a rare subtype of multiple myeloma, accounting for approximately 2-3% of cases. The study, which included 43 patients from 8 Polish hematology centers, found that the median overall survival was 103 months. The overall response rate was 84.6%, and factors contributing to worse overall survival included International Staging System stage 3, anemia, renal insufficiency, and low serum albumin levels. The researchers concluded that including NSMM patients in clinical trials is essential to assess prognosis, treatment efficacy, and clinical outcomes. [Extracted from the article] |
